Products - Blood conditions | Topic | NICE

Showing 8 products

Date | Sort by Title

Status: In developmentRemove ‘Status: In development’ filter

Sodium zirconium cyclosilicate for treating hyperkalaemia [ID1293]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
21 August 2019
Avatrombopag and lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing an elective procedure [ID1520]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
26 February 2020
Andexanet alfa for reversing anticoagulation [ID1101]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
4 March 2020
Patiromer for treating hyperkalaemia [ID877]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Mepolizumab for treating eosinophilic granulomatosis with polyangiitis ID1186
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Caplacizumab for treating acute acquired thrombotic thrombocytopenic purpura ID1185
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Fedratinib for splenomegaly and symptoms in myelofibrosis [ID1501]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly ID1596
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC